生物等效性
医学
头孢哌酮
舒巴坦钠
最大值
药代动力学
药理学
置信区间
交叉研究
肌肉注射
麻醉
内科学
抗生素
化学
生物化学
亚胺培南
替代医学
病理
抗生素耐药性
安慰剂
作者
Sayam Kaewvichit,Songwut Yotsawimonwat,Wandee Taesotikul,Wirat Niwatananun,Chadarat Duangrat,Chokchai Wongsinsup,Satawat Thongsawat,Parichat Salee
出处
期刊:Journal of the Medical Association of Thailand
[Medical Association of Thailand]
日期:2008-11-01
卷期号:91 (11): 1760-4
被引量:2
摘要
To perform a bioequivalence study of the two 1.5 g cefoperazone (1.0 g) and sulbactam (0.5 g) between Cefper and Sulperazon injections.The present study was performed in 24 Thai healthy male volunteers who were intramuscularly injected a single dose of 1.5 g cefoperazone and sulbactam. A single dose, two periods, two sequences, double blind randomized crossover with a one-week washout period was used. Blood samples were collected before and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours after intramuscular injection and determined for cefoperazone and sulbactam plasma concentration by validated HPLC-UV methods. The pharmacokinetic parameters were analyzed by noncompartmental analysis and the ANOVA was carried out.Tax of both cefoperazone and sulbactam for volunteers who were injected with either Cefper or Sulperazon injection were not significantly different (p > 0.05). The 90% confidence intervals of the log of ratio of either C(max) or AUC(last) or AUC(inf) of both cefoperazone and sulbactam between 1.5 g Cefper and Sulperazon injections were within the bioequivalence range of 0.80-1.25.The 1.5 g cefoperazone and sulbactam injection of Cefper and Sulperazone used in the present study are bioequivalent.
科研通智能强力驱动
Strongly Powered by AbleSci AI